MAVS
MAVS (mitochondrial antiviral signalling protein, also known as VISA, IPS-1, Cardif and KIAA1271) is an adapter protein required for innate immune defence against viruses. It links cytosolic detection of viral dsRNA to the induction of interferon and other antiviral cytokines. Browse Assay Genie's current range of MAVS research reagents below, or read on for the biology behind the target.
MAVS acts as an adapter downstream of the intracellular dsRNA sensors DHX33, RIGI and IFIH1/MDA5, which detect dsRNA produced during viral replication. From this point it coordinates pathways that activate NF-kappa-B, IRF3 and IRF7, leading to induction of antiviral cytokines such as IFNB and RANTES (CCL5). It may also act in the same pathways after TLR3 detects extracellular dsRNA.
The protein works from more than one organelle, and the two pools act in sequence. On viral infection, peroxisomal MAVS drives rapid, interferon-independent expression of defence factors that give short-term protection. Mitochondrial MAVS activates an interferon-dependent pathway with delayed kinetics, which amplifies and stabilises the antiviral response. Together they create an antiviral cellular state. MAVS is also involved in NLRP3 inflammasome activation by mediating recruitment of NLRP3 to mitochondria, and it may protect cells from apoptosis.
The MAVS gene encodes an intermediary protein needed for virus-triggered beta interferon signalling. It is required to activate the transcription factors that regulate beta interferon expression, and so contributes to antiviral innate immunity. The protein is localised to the mitochondrial outer membrane and to peroxisomes. HGNC places it in the caspase recruitment domain containing gene group. The mouse and rat orthologs are both named Mavs, which is useful when selecting an MAVS antibody, MAVS ELISA kit or MAVS protein for comparative work.
MAVS is required for innate defence against viruses, relaying dsRNA detection into NF-kappa-B, IRF3 and IRF7 activation.
MAVS is necessary for virus-triggered beta interferon pathways and for induction of cytokines such as IFNB and RANTES (CCL5).
MAVS mediates NLRP3 recruitment to mitochondria, linking antiviral signalling to NLRP3 inflammasome activation.
Peroxisomal and mitochondrial MAVS act sequentially, with rapid interferon-independent and delayed interferon-dependent responses respectively.
MAVS is an adapter required for innate immune defence against viruses. Acting downstream of DHX33, RIGI and IFIH1/MDA5, it coordinates activation of NF-kappa-B, IRF3 and IRF7 and the induction of antiviral cytokines such as IFNB and RANTES (CCL5). It also helps recruit NLRP3 to mitochondria.
MAVS is the HGNC symbol for mitochondrial antiviral signalling protein. Other names in use are VISA, IPS-1, Cardif and KIAA1271. These all refer to the same gene and protein, so searching under any of them is useful when reviewing the literature.
MAVS localises to the mitochondrial outer membrane and to peroxisomes, where the two pools act sequentially in antiviral signalling. Orthologs named Mavs exist in mouse and rat; check the datasheet of any product for its validated reactivity.
Upstream dsRNA sensors, downstream transcription factors, antiviral cytokines and inflammasome components linked to MAVS signalling.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q7Z434; product specifications from Assay Genie datasheets.